Search Results Within Category "Arthritis & Rheumatic Diseases"
MT2024-43: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis (Regulate-RA)
The study evaluates the safety and effects of a novel regulatory CARTreg cell-based autoimmune and inflammatory disease therapy for the treatment of rheumatoid arthritis. The therapy is an autologous (using the patient's own cells) Treg cell therapy that targets proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.
• adult-onset, moderate-to-severe rheumatoid arthritis (RA)
• Body mass index (BMI) <35 kg/m^2
• inadequate response to or unable to tolerate available RA therapies
• willing to use highly effective methods of contraception
• see link to clinicaltrials.gov for complete inclusion criteria
• major surgery within 12 weeks prior to screening or planned within 12 months
• uncontrolled heart, lung, kidney, liver, endocrine, or gastrointestinal disease
• recurrent infections or active infection
• see link to clinicaltrials.gov for complete exclusion criteria
D2D: Tyrannosaurus Flex: Finding the "Fair-ly Normal" Grip
How strong is your squeeze? We’re inviting kids aged 2-12 to test their grip and help us establish new standards for hand strength. Your contribution allows our team to create more inclusive, accurately calibrated technology that works for everybody. Stop by the Minnesota State Fair Research Building for a Tyrannosaurus Flex to help us find the Fair-ly Normal Grip and help us build the future of interactive play!
• ages 2-12 years old
• musculoskeletal, neurological, or neuromuscular conditions affecting upper limb strength or function
• diagnosis of a systemic condition affecting the musculoskeletal or nervous system
• previous hand, wrist, or upper limb surgery
• history of hand, wrist, or upper limb trauma
• current pain in either hand or upper limb
D2D: Normative Benchmarks and MP Collapse Indicators for Dynamic Thumb Stability: Findings from the Hoover Collapse Test
Curious about your pinch strength? Take part in a short thumb test and help researchers at the Minnesota State Fair Research Building learn more about hand function.
• ages 18 years or older
• able to perform a pinch with at least one hand
• have central or peripheral nervous system conditions affecting hand function
• have had hand or wrist surgery, fixed contractures, or pain that prevents pinch performance
D2D: Establishing normative range of motion for scapular protraction and retraction among a healthy adult population
Help researchers at the Minnesota State Fair Research Building understand normal shoulder blade movement by participating in a 10–15 minute motion assessment.
• ages 18 years or older
• no known injury/pathology that would impair movement of the scapula
Determining Normative Hand Measurements to Optimize Hand Reconstruction Aesthetic Outcomes
Help researchers at the Minnesota State Fair Research Building learn how people naturally hold a pen while writing. This information may improve therapies that support handwriting skills.
• ages 5 years and older
CONQUER Protocol Number 001: COllaborative, National QUality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma) Patients (CONQUER)
The purpose of this study is to develop a cohort of patients with early scleroderma, and to collect data on clinical outcomes, radiological tests, laboratory tests and to obtain biological specimens for testing.We hope to explore medical care and the impact of SSc on patients' daily lives through various questionnaires that will be collected during study participation. By looking at all of the areas mentioned, we hope to find out information about SSc that will help treat future patients, develop new treatments, and work towards a cure.
• at least 18 years old
• have a diagnosis of systemic sclerosis
• less than 5 years from onset of first symptom attributed to systemic sclerosis
• cognitive impairment that interferes with ability to participate in the study
• unable to speak, read, and write English
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy (BLOSSOM)
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect various organs of the body, especially the skin, joints, blood, kidneys and central nervous system. "Chronic" means that it can last for a long time. "Autoimmune" means that there is a disorder of the immune system, which, instead of protecting the body from bacteria and viruses, attacks the one’s own tissues. We are doing this study to see if the investigational medication called anifrolumab may have an effect in treating pediatric SLE, to see how well it is tolerated or how safe it is, to measure levels of anifrolumab in the blood and learn more about the disease and associated health problems.
• 5 years to less than 18 years old
• weight at lest 15 kg (33 pounds)
• diagnosis of Systemic Lupus Erythematosus (SLE)
• being treated with prednisone, or antimalarial drugs
• no active or chronic TB or contact with someone who has TB
• females and males must be willing to use birth control during the study
• see link to clinicaltrials.gov for complete inclusion & exclusion criteria
• history of suicidal ideation within the past 6 months; or any suicidal behavior within the past 12 months
• history of multiple infections requiring hospitalization and IV antibiotics over the past year
• history of cancer
• history of severe COVID-19 infection
• prior treatment with anifrolumab